Core Alternative Capital’s Edwards Lifesciences EW Stock Holding History

Core Alternative Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17	Closed	-$1.32K	–	263
2025 Q3	$1.32K	Hold	17	–	–	﹤0.01%	280
2025 Q2	$1.33K	Hold	17	–	–	﹤0.01%	271
2025 Q1	$1.23K	Hold	17	–	–	﹤0.01%	271
2024 Q4	$1.26K	Hold	17	–	–	﹤0.01%	293
2024 Q3	$1.12K	Hold	17	–	–	﹤0.01%	306
2024 Q2	$1.57K	Hold	17	–	–	﹤0.01%	273
2024 Q1	$1.63K	Sell	17 -310	-95%	-$26K	﹤0.01%	266
2023 Q4	$24.9K	Sell	327 -37	-10%	-$2.57K	﹤0.01%	208
2023 Q3	$25.2K	Hold	364	–	–	﹤0.01%	229
2023 Q2	$34.3K	Buy	364 +11	+3%	+$956	0.01%	182
2023 Q1	$29.2K	Buy	353 +173	+96%	+$13.6K	﹤0.01%	200
2022 Q4	$13.4K	Sell	180 -126	-41%	-$9.71K	﹤0.01%	252
2022 Q3	$25K	Buy	306 +24	+9%	+$2.31K	﹤0.01%	200
2022 Q2	$27K	Buy	282 +49	+21%	+$5.07K	0.01%	196
2022 Q1	$27K	Buy	233 +195	+513%	+$21.9K	0.01%	188
2021 Q4	$5K	Buy	+38	New	+$4.43K	﹤0.01%	183

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Core Alternative Capital's EW Position: Q4 2025 in Review

Core Alternative Capital sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 17 shares — an estimated $1.32K sold.

Core Alternative Capital first reported a position in EW in Q4 2021 and held it in 16 quarters. The position peaked at $34.3K in Q2 2023. 1,315 funds tracked by Wall St. Rank hold EW as of Q4 2025.

Core Alternative Capital reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
Core Alternative Capital sold 17 Edwards Lifesciences shares in Q4 2025, an estimated $1.32K.
Core Alternative Capital first reported a position in Edwards Lifesciences in Q4 2021 and held it in 16 quarters.
Core Alternative Capital's Edwards Lifesciences position peaked at $34.3K in Q2 2023.
1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Core Alternative Capital's 13F filing for Q4 2025, filed 2 Feb 2026.